🇺🇸 FDA
Pipeline program

A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo

NN9490-8152

Phase 1 other active

Quick answer

A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo for Obesity is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Novo Nordisk A/S
Indication
Obesity
Phase
Phase 1
Modality
other
Status
active

Clinical trials